Sagar Lonial, MD, ACTSI investigator, professor and vice chairman of clinical affairs at Emory University School of Medicine department of hematology and medical oncology, and director of translational research for the B-cell malignancy program at Winship Cancer Institute
ASCO Post | Unraveling the molecular complexity of multiple myeloma
April 15, 2014
Lab Land | Cellular response to stress: autophagy
November 13, 2013
Lonial received a top award from the Multiple Myeloma Research Foundation (MMRF), the MMRF Accelerator Award. He was recognized for his outstanding efforts and exceptional contributions to starting new clinical trials through the Multiple Myeloma Research Consortium and rapidly enrolling patients in those trials.
Lonial was also a recipient of the 2013 Emory Millipub Award. The distinction is given to faculty with papers cited one thousand times or more.
He received the Celgene 2012 Young Investigator Award for Clinical Research in Hematology.
Winship opened a new trial of a CD38 antibody called daratumumab. Lonial is principal investigator of the study at Winship. According to Lonial, daratumumab is one of the most exciting new agents in multiple myeloma, and there are very few sites that have the drug available. Lonial and his team have started screening patients and delivered the first dose overall on the study. The trial opened very rapidly (close to 45 days) and the first two patients have already started treatment. This agent falls into the new FDA category of breakthrough designation, and thus, it will likely be the registration study for accelerated approval.
LA Canada | Successful blood cancer therapy identified
May 30, 2012
Genetic Engineering & Biotechnology News | Partnership seeks multiple myeloma biomarkers and drugs
September 24, 2012
Nature.com | Next-generation proteasome inhibitor approved in multiple myeloma
November 8, 2012
Emory Health Sciences | When Bone Marrow Goes Bad
In the News 2011-2012